(Alliance News) - Shares in BATM Advanced Communications Ltd surged on Tuesday after the company started shipping a new Covid-19 antibody test to European customers.
Shares in the bio-medical and cyber security solutions provider were up 19% at 69.16 pence each in London.
The company's Adaltis subsidiary has launched a CE-certified enzyme-linked immunosorbent assay serological test that detects antibodies produced against Covid-19 present in a person's blood.
Antibodies are proteins produced by a human body in response to harmful substances called antigens, such as a virus.
The new ELISA Serological test measures the amount of various antibodies present in the blood of a human body when it is responding to a specific infection, like Covid-19. The test detects a human body's immune response to the infection caused by the virus rather than detecting the virus itself.
BATM said the new test kit is designed to test for antibodies produced within four to five days of the immune system response - as well as antibodies produced after a few weeks and stay present in the body for at least several months.
The ELISA Serological test are complementary to BATM's other two Covid-19 diagnostics kits, both of which are designed to detect the presence of the virus rather than the immune response to it.
By Tapan Panchal; tapanpanchal@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Batm Advanced (BVC)